VRTX logo

VRTX Total liabilities

annual total liabilities:

$6.68B+$1.18B(+21.34%)
December 31, 2024

Summary

  • As of today (August 18, 2025), VRTX annual total liabilities is $6.68 billion, with the most recent change of +$1.18 billion (+21.34%) on December 31, 2024.
  • During the last 3 years, VRTX annual total liabilities has risen by +$3.35 billion (+100.48%).
  • VRTX annual total liabilities is now at all-time high.

Performance

VRTX Total liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherVRTXbalance sheet metrics

quarterly total liabilities:

$6.86B+$477.10M(+7.47%)
June 30, 2025

Summary

  • As of today (August 18, 2025), VRTX quarterly total liabilities is $6.86 billion, with the most recent change of +$477.10 million (+7.47%) on June 30, 2025.
  • Over the past year, VRTX quarterly total liabilities has increased by +$1.50 billion (+28.07%).
  • VRTX quarterly total liabilities is now at all-time high.

Performance

VRTX quarterly total liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherVRTXbalance sheet metrics

Total liabilities Formula

Total Liabilities = Current Liabilities + Long-Term Liabilities

VRTX Total liabilities Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+21.3%+28.1%
3 y3 years+100.5%+88.0%
5 y5 years+199.2%+154.4%

VRTX Total liabilities Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+100.5%at high+88.0%
5 y5-yearat high+199.2%at high+154.4%
alltimeall timeat high>+9999.0%at high>+9999.0%

VRTX Total liabilities History

DateAnnualQuarterly
Jun 2025
-
$6.86B(+7.5%)
Mar 2025
-
$6.38B(-4.4%)
Dec 2024
$6.68B(+21.3%)
$6.68B(+1.1%)
Sep 2024
-
$6.61B(+23.4%)
Jun 2024
-
$5.36B(-0.2%)
Mar 2024
-
$5.37B(-2.5%)
Dec 2023
$5.51B(+29.9%)
$5.51B(+5.6%)
Sep 2023
-
$5.21B(+6.9%)
Jun 2023
-
$4.88B(+7.4%)
Mar 2023
-
$4.54B(+7.2%)
Dec 2022
$4.24B(+27.2%)
$4.24B(+15.3%)
Sep 2022
-
$3.68B(+0.8%)
Jun 2022
-
$3.65B(+8.9%)
Mar 2022
-
$3.35B(+0.5%)
Dec 2021
$3.33B(+8.7%)
$3.33B(+7.9%)
Sep 2021
-
$3.09B(+2.1%)
Jun 2021
-
$3.03B(-3.5%)
Mar 2021
-
$3.13B(+2.3%)
Dec 2020
$3.06B(+37.2%)
$3.06B(-3.3%)
Sep 2020
-
$3.17B(+17.5%)
Jun 2020
-
$2.70B(+10.9%)
Mar 2020
-
$2.43B(+8.9%)
Dec 2019
$2.23B(+23.3%)
$2.23B(-1.2%)
Sep 2019
-
$2.26B(+15.2%)
Jun 2019
-
$1.96B(+7.9%)
Mar 2019
-
$1.82B(+0.5%)
Dec 2018
$1.81B(+20.4%)
$1.81B(+7.4%)
Sep 2018
-
$1.69B(+4.1%)
Jun 2018
-
$1.62B(+6.5%)
Mar 2018
-
$1.52B(+1.2%)
Dec 2017
$1.50B(-3.5%)
$1.50B(+7.8%)
Sep 2017
-
$1.40B(-1.6%)
Jun 2017
-
$1.42B(+12.2%)
Mar 2017
-
$1.26B(-18.9%)
Dec 2016
$1.56B(+10.9%)
$1.56B(+11.2%)
Sep 2016
-
$1.40B(+1.5%)
Jun 2016
-
$1.38B(+0.6%)
Mar 2016
-
$1.37B(-2.4%)
Dec 2015
$1.40B(+13.4%)
$1.41B(+3.5%)
Sep 2015
-
$1.36B(+2.4%)
Jun 2015
-
$1.33B(+13.5%)
Mar 2015
-
$1.17B(-5.7%)
Dec 2014
$1.24B(+28.7%)
$1.24B(-0.9%)
Sep 2014
-
$1.25B(+32.2%)
Jun 2014
-
$945.55M(-2.1%)
Mar 2014
-
$966.23M(+0.4%)
Dec 2013
$962.64M(-36.9%)
$962.64M(-12.2%)
Sep 2013
-
$1.10B(+5.8%)
Jun 2013
-
$1.04B(-26.8%)
Mar 2013
-
$1.42B(-7.2%)
Dec 2012
$1.53B(+23.1%)
$1.53B(+4.9%)
Sep 2012
-
$1.45B(+6.8%)
Jun 2012
-
$1.36B(+9.8%)
Mar 2012
-
$1.24B(+0.1%)
Dec 2011
$1.24B(+1.4%)
$1.24B(-9.0%)
Sep 2011
-
$1.36B(+3.6%)
Jun 2011
-
$1.31B(+14.6%)
Mar 2011
-
$1.15B(-6.1%)
Dec 2010
$1.22B(+42.2%)
$1.22B(-1.4%)
Sep 2010
-
$1.24B(+49.8%)
Jun 2010
-
$827.07M(+6.1%)
Mar 2010
-
$779.69M(-9.2%)
Dec 2009
$859.14M(+15.8%)
$859.14M(-10.9%)
Sep 2009
-
$964.75M(+35.7%)
Jun 2009
-
$710.82M(-17.3%)
Mar 2009
-
$859.03M(+15.8%)
Dec 2008
$741.61M
$741.61M(+3.3%)
Sep 2008
-
$717.66M(-1.8%)
Jun 2008
-
$730.88M(+24.9%)
DateAnnualQuarterly
Mar 2008
-
$585.25M(+77.3%)
Dec 2007
$330.18M(-20.6%)
$330.18M(+2.2%)
Sep 2007
-
$323.11M(-6.7%)
Jun 2007
-
$346.49M(+3.8%)
Mar 2007
-
$333.80M(-19.7%)
Dec 2006
$415.64M(+34.2%)
$415.64M(+5.4%)
Sep 2006
-
$394.34M(-12.5%)
Jun 2006
-
$450.48M(+54.4%)
Mar 2006
-
$291.75M(-5.8%)
Dec 2005
$309.82M(-39.3%)
$309.82M(-25.7%)
Sep 2005
-
$417.26M(-12.0%)
Jun 2005
-
$473.94M(-3.8%)
Mar 2005
-
$492.72M(-3.4%)
Dec 2004
$510.01M(-4.1%)
$510.01M(+2.0%)
Sep 2004
-
$500.04M(-2.7%)
Jun 2004
-
$513.76M(+0.3%)
Mar 2004
-
$512.09M(-3.7%)
Dec 2003
$531.57M(+21.6%)
$531.57M(+3.9%)
Sep 2003
-
$511.39M(+7.9%)
Jun 2003
-
$473.94M(+7.7%)
Mar 2003
-
$440.04M(+0.7%)
Dec 2002
$437.14M(-2.8%)
$437.14M(+3.4%)
Sep 2002
-
$422.86M(-0.2%)
Jun 2002
-
$423.79M(-0.4%)
Mar 2002
-
$425.40M(-5.4%)
Dec 2001
$449.78M(+16.5%)
$449.78M(+0.8%)
Sep 2001
-
$446.08M(+15.7%)
Jun 2001
-
$385.49M(+1.8%)
Mar 2001
-
$378.84M(-1.9%)
Dec 2000
$385.98M(+1562.9%)
$385.98M(-29.6%)
Sep 2000
-
$547.96M(+169.7%)
Jun 2000
-
$203.21M(+4.1%)
Mar 2000
-
$195.19M(+741.0%)
Dec 1999
$23.21M(+15.3%)
$23.21M(+26.6%)
Sep 1999
-
$18.33M(-8.6%)
Jun 1999
-
$20.05M(-0.7%)
Mar 1999
-
$20.19M(+0.3%)
Dec 1998
$20.13M(+2.7%)
$20.13M(+7.2%)
Sep 1998
-
$18.79M(+20.7%)
Jun 1998
-
$15.56M(+4.3%)
Mar 1998
-
$14.92M(-23.9%)
Dec 1997
$19.60M(+54.7%)
$19.60M(+14.0%)
Sep 1997
-
$17.20M(+17.0%)
Jun 1997
-
$14.70M(+2.1%)
Mar 1997
-
$14.40M(+13.4%)
Dec 1996
$12.67M(-7.6%)
$12.70M(+29.6%)
Sep 1996
-
$9.80M(-18.3%)
Jun 1996
-
$12.00M(+0.8%)
Mar 1996
-
$11.90M(-13.1%)
Dec 1995
$13.71M(+28.2%)
$13.70M(+7.9%)
Sep 1995
-
$12.70M(-7.3%)
Jun 1995
-
$13.70M(+25.7%)
Mar 1995
-
$10.90M(+1.9%)
Dec 1994
$10.70M(-6.8%)
$10.70M(-10.8%)
Sep 1994
-
$12.00M(+6.2%)
Jun 1994
-
$11.30M(+20.2%)
Mar 1994
-
$9.40M(-18.3%)
Dec 1993
$11.47M(+59.5%)
$11.50M(+12.7%)
Sep 1993
-
$10.20M(+21.4%)
Jun 1993
-
$8.40M(+3.7%)
Mar 1993
-
$8.10M(+14.1%)
Dec 1992
$7.19M(+47.5%)
$7.10M(+10.9%)
Sep 1992
-
$6.40M(+8.5%)
Jun 1992
-
$5.90M(+20.4%)
Mar 1992
-
$4.90M(0.0%)
Dec 1991
$4.88M(+21.9%)
$4.90M(+6.5%)
Sep 1991
-
$4.60M(-2.1%)
Jun 1991
-
$4.70M(+17.5%)
Dec 1990
$4.00M
$4.00M

FAQ

  • What is Vertex Pharmaceuticals Incorporated annual total liabilities?
  • What is the all time high annual total liabilities for Vertex Pharmaceuticals Incorporated?
  • What is Vertex Pharmaceuticals Incorporated annual total liabilities year-on-year change?
  • What is Vertex Pharmaceuticals Incorporated quarterly total liabilities?
  • What is the all time high quarterly total liabilities for Vertex Pharmaceuticals Incorporated?
  • What is Vertex Pharmaceuticals Incorporated quarterly total liabilities year-on-year change?

What is Vertex Pharmaceuticals Incorporated annual total liabilities?

The current annual total liabilities of VRTX is $6.68B

What is the all time high annual total liabilities for Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals Incorporated all-time high annual total liabilities is $6.68B

What is Vertex Pharmaceuticals Incorporated annual total liabilities year-on-year change?

Over the past year, VRTX annual total liabilities has changed by +$1.18B (+21.34%)

What is Vertex Pharmaceuticals Incorporated quarterly total liabilities?

The current quarterly total liabilities of VRTX is $6.86B

What is the all time high quarterly total liabilities for Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals Incorporated all-time high quarterly total liabilities is $6.86B

What is Vertex Pharmaceuticals Incorporated quarterly total liabilities year-on-year change?

Over the past year, VRTX quarterly total liabilities has changed by +$1.50B (+28.07%)
On this page